Plasma pharmacokinetics and tissue disposition of novel dextran-methylprednisolone conjugates with peptide linkers in rats

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1626-1637

  Penugonda, Suman ^a   Agarwal, Hitesh K ^b   Parang, Keykavous ^b   Mehvar, Reza ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Dextran prodrugs; Immunosuppression; Liver targeting; Macromolecular prodrugs; Methylprednisolone; Peptide linkers; Pharmacokinetics; Tissue distribution

Indexed keywords

DEXTRAN; METHYLPREDNISOLONE; PRODRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY; LIVER; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SPLEEN; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

EID: 76649093573     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21934     Document Type: Article

References (41)

1. Evans R, Manninen D, Dong F, Ascher N, Frist W, Hansen J, Kirklin J, Perkins J, Pirsch J, Sanfilippo F. 1993. Immunosuppressive therapy as a determinant of transplantation outcomes. Transplantation 55:1297-1305.
2. Wiesner R, Ludwig J, Krom R, Steers J, Porayko M, Gores G, Hay J. 1994. Treatment of early cellular rejection following liver transplantation with intravenous methylprednisolone. The effect of dose on response. Transplantation 58:1053-1056.
3. Volpin R, Angeli P, Galioto A, Fasolato S, Neri D, Barbazza F, Merenda R, Del Piccolo F, Strazzabosco M, Casagrande F, Feltracco P, Sticca A, Merkel C, Gerunda G, Gatta A. 2002. Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: A controlled clinical trial. Liver Transpl 8:527-534.
4. Millis JM. 1999. Treatment of liver allograft rejection. Liver Transpl Surg 5:S98-S106.
5. Adams D, Neuberger JM. 1992. Treatment of acute rejection. Semin Liver Dis 12:80-87.
6. Stubbs S, Morrell R. 1973. Intravenous methylprednisolone sodium succinate: Adverse reactions reported in association with immunosuppressive therapy. Transplant Proc 5:1145-1146.
7. McDougal BA, Whittier FC, Cross DE. 1976. Sudden death after bolus steroid therapy for acute rejection. Transplant Proc 8:493-496.
8. Bocanegra TS, Castaneda MO, Espinoza LR, Vasey FB, Germain BF. 1981. Sudden death after methylprednisolone pulse therapy. Ann Intern Med 95: 122.
9. Gardiner PV, Griffiths ID. 1990. Sudden death after treatment with pulsed methylprednisolone. Br Med J 300:125.
10. Moses RE, McCormick A, Nickey W. 1981. Fatal arrhythmia after pulse methylprednisolone therapy. Ann Intern Med 95:781-782.
11. Guillen EL, Ruiz AM, Bugallo JB. 1998. Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient. Am J Kidney Dis 32:E4.
12. McLuckie AE, Savage RW. 1993. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 104:622-623.
13. Ayoub WT, Torretti D, Harrington TM. 1983. Central nervous system manifestations after pulse therapy for systemic lupus erythematosus. Arthritis Rheum 26:809-810.
14. Suchman AL, Condemi JJ, Leddy JP. 1983. Seizure after pulse therapy with methyl prednisolone. Arthritis Rheum 26:117.
15. Cerilli J, Miller JA. 1972. The effect of massive pulse steroid therapy on the water content of the rat brain. Transplantation 14:403-405.
16. El-Dahr S, Chevalier RL, Gomez RA, Campbell FG. 1987. Seizures and blindness following intravenous pulse methylprednisolone in a renal transplant patient. Int J Pediatr Nephrol 8:87-90.
17. Kozeny GA, Quinn JP, Bansal VK, Vertuno LL, Hano E. 1987. Pneumocystis carinii pneumonia: A lethal complication of "pulse" methylprednisolone therapy. Int J Artif Organs 10:304-306.
18. Bonnotte B, Chauffert B, Martin F, Lorcerie B. 1998. Side-effects of high-dose intravenous (pulse) methylprednisolone therapy cured by potassium infusion. Br J Rheumatol 37:109.
19. Zhang X, Mehvar R. 2001. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: Plasma and tissue disposition. J Pharm Sci 90:2078-2087.
20. Mehvar R, Hoganson DA. 2000. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: Immunosuppressive effects after in vivo administration to rats. Pharm Res 17:1402-1407.
21. Chimalakonda AP, Mehvar R. 2003. Dextranmethylprednisolone succinate as a prodrug of methylprednisolone: Local immunosuppressive effects in liver after systemic administration to rats. Pharm Res 20:198-204.
22. Chimalakonda AP, Montgomery DL, Weidanz JA, Shaik IH, Nguyen JH, Lemasters JJ, Kobayashi E, Mehvar R. 2006. Attenuation of acute rejection in a rat liver transplantation model by a liver-targeted dextran prodrug of methylprednisolone. Transplantation 81:678-685.
23. Zhang X, Mehvar R. 2001. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: Dose-dependent pharmacokinetics in rats. Int J Pharm 229:173-182.
24. Penugonda S, Kumar A, Agarwal HK, Parang K, Mehvar R. 2008. Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: Effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates. J Pharm Sci 97:2649-2664.
25. Zhang SQ, Thorsheim HR, Penugonda S, Pillai VC, Smith QR, Mehvar R. 2009. Liquid chromatography-tandem mass spectrometry for the determination of methylprednisolone in rat plasma and liver after intravenous administration of its liver-targeted dextran prodrug. J Chromatogr B Anal Technol Biomed Life Sci 877:927-932.
26. Mehvar R, Dann RO, Hoganson DA. 2000. Simultaneous analysis of methylprednisolone, methylprednisolone succinate, and endogenous corticosterone in rat plasma. J Pharm Biomed Anal 22:1015-1022.
27. Mehvar R. 2000. High-performance size-exclusion chromatographic analysis of dextran-methylprednisolone hemisuccinate in rat plasma. J Chromatogr B 744:293-298.
28. Mehvar R, Robinson MA, Reynolds JM. 1994. Molecular weight dependent tissue accumulation of dextrans: In vivo studies in rats. J Pharm Sci 83:1495-1499.
29. Bernareggi A, Rowland M. 1991. Physiologic modeling of cyclosporine kinetics in rat and man. J Pharmacokinet Biopharm 19:21-50.
30. Bailer AJ. 1988. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16: 303-309.
31. Harada M, Sakakibara H, Yano T, Suzuki T, Okuno S. 2000. Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J Control Release 69:399-412.
32. Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, Sakamura Y, Imai J, Kawaguchi T, Tsujihara K. 2000. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res 60:2988-2995.
33. Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, van den Heuvel IJ, Beijnen JH, Voest EE, Schellens JH. 2008. Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clin Cancer Res 14:7535-7544.
34. Kumazawa E, Ochi Y. 2004. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: Potent antitumor activities in various murine tumor models. Cancer Sci 95:168-175.
35. Soepenberg O, de Jonge MJ, Sparreboom A, de Bruin P, Eskens FA, de Heus G, Wanders J, Cheverton P, Ducharme MP, Verweij J. 2005. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 11:703-711.
36. Chau Y, Tan FE, Langer R. 2004. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjug Chem 15:931-941.
37. Chau Y, Dang NM, Tan FE, Langer R. 2006. Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinaseoverexpressing tumor xenograft model. J Pharm Sci 95:542-551.
38. Takakura Y, Fujita T, Hashida M, Sezaki H. 1990. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm Res 7:339-346.
39. Mehvar R, Robinson MA, Reynolds JM. 1995. Dose dependency of the kinetics of dextrans in rats: Effects of molecular weight. J Pharm Sci 84:815-818.
40. Lake JR, Licko V, Van Dyke RW, Scharschmidt BF. 1985. Biliary secretion of fluid-phase markers by the isolated perfused rat liver. Role of transcellular vesicular transport. J Clin Invest 76:676-684.
41. Stock RJ, Cilento EV, McCuskey RS. 1989. A quantitative study of fluorescein isothiocyanate-dextran transport in the microcirculation of the isolated perfused rat liver. Hepatology 9: 75-82.